Study to access safety of Durvalumab in Indian adult patients with locally advanced NSCLC

Study identifier:D133HC00003

ClinicalTrials.gov identifier:NCT04416633

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)

Medical condition

unresectable non-small cell lung cancer (NSCLC)

Phase

Phase 4

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Actual Enrollment

100

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 30 Nov 2021
Primary Completion Date: 27 Oct 2023
Study Completion Date: 27 Oct 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria